Faster trials.
Broader access.
One AI-powered platform.

Introducing your competitive advantage. Inato’s AI-powered platform connects you to engaged sites at scale, so you can accelerate drug development and ultimately bring care to the patients who need it most.

Dashboard displaying clinical trials status: Phase 3 Brinkamab for Severe Asthma setup in progress, Moderate Asthma and Hidradenitis Suppurativa with ongoing selection, and Atopic Dermatitis enrolling with 35 patients pre-screened.
Two research site cards with hospital photos, names, contacts, locations, attribute icons, and purple select buttons.
Interface with the heading 'Find the right mix of sites!' and subheading 'Heights Pharma – Phase 3 – Brinkamab for Asthma' above a text input field labeled 'Ask your question...' with a purple send button.
Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.

Innovating with
Forward-Thinking Pharma Leaders

We co-develop our technology with forward-thinking pharma and site leaders to ensure every trial is faster, more efficient, and more inclusive.

Sanofi logo
Amgen
Pfizer logo
Lilly
Kailero brand logo text.
AstraZeneca logo
Sanofi
AMGEN
Pfizer
Lilly
Twoja Przychodnia
AstraZeneca

Why Leading Sponsors Partner with Inato

Partner with
proven sites

Work with motivated, high-performing sites that match your protocol and help you reach underrepresented communities.

Reach more
patients, everywhere

Connect with 6,000+ committed research sites across 50+ countries to reach the right patients, faster.

Everything in
one platform

From early planning to patient enrollment, simplify how you run trials, all in one place.

How we do it

Inato’s platform is built to support you from early planning to enrollment.  Make faster, more informed decisions with our co-developed AI capabilities and site insights at scale.

Charts showing US patient population demographics and barriers to recruitment with comparison between US and Ex-US, plus treatment options impact and site comments on trial visit challenges.
Pie chart showing US patient population by race: Hispanic 50%, White 26%, Black 19%, Asian 3%, Other 2%.
Comparison cards for two clinical research sites: Abbott Northwestern Hospital led by Oscar G. Guttierez in Vineland, NJ, with 20 patients IVC, 6 PI trials in NSCLC, and 100% requirements met; and Applied Clinical Research led by Alexandra Brown, M.D. in Miami, FL, with 3 patients IVC, 4 trials in NSCLC, and 80% requirements met.
Chat interface suggesting three best clinical trial sites: Abbott Northwestern Hospital, Applied Clinical Research, and Clinical Research, with explanation of diversity and speed benefits.
Patient pre-screening table for Phase 3 Brinkamab severe asthma study showing six patients with their prescreening percentages and status: three to screen with 80-92%, two failed with 20-30%, and one to review at 10%.
Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.
Text highlighting top criteria for ineligibility as any other active disease or condition interfering with asthma assessment, with 31 patients excluded.
Charts showing US patient population demographics and barriers to recruitment with comparison between US and Ex-US, plus treatment options impact and site comments on trial visit challenges.
Pie chart showing US patient population by race: Hispanic 50%, White 26%, Black 19%, Asian 3%, Other 2%.
01

Early planning

Use site insights at scale to inform your strategy and design trials that are both inclusive and efficient.

Comparison cards for two clinical research sites: Abbott Northwestern Hospital led by Oscar G. Guttierez in Vineland, NJ, with 20 patients IVC, 6 PI trials in NSCLC, and 100% requirements met; and Applied Clinical Research led by Alexandra Brown, M.D. in Miami, FL, with 3 patients IVC, 4 trials in NSCLC, and 80% requirements met.
Chat interface suggesting three best clinical trial sites: Abbott Northwestern Hospital, Applied Clinical Research, and Clinical Research, with explanation of diversity and speed benefits.
02

AI  site selection

Confidently select the mix of sites that best aligns with your trial goals, powered by AI insights that guide better decisions.

Patient pre-screening table for Phase 3 Brinkamab severe asthma study showing six patients with their prescreening percentages and status: three to screen with 80-92%, two failed with 20-30%, and one to review at 10%.
Line chart showing a steady increase in patients pre-screened from December 29 to March 13, reaching a total of 35 patients.
Text highlighting top criteria for ineligibility as any other active disease or condition interfering with asthma assessment, with 31 patients excluded.
03

AI patient pre‑screening

Reduce site burden, accelerate chart review, and gain visibility with real-time insights by site, trial, and indication.

How it all
works together

Each step powers the next, creating a seamless flow from planning to performance. Sponsors gain early protocol insights, engage high-performing sites faster, and track real-time site performance to optimize every stage of the trial.

Real impact and proven results

Sites

Inato Integrates With eClinPro To Streamline Patient Screening and Enrollment

-
Inato
5
min
April 15, 2026
Inato Integrates With eClinPro To Streamline Patient Screening and Enrollment
Sponsors

Weight Loss Study: AI Pre-Screening

Site Spotlight

181 Hours and $4,500 Saved: Inside One Weight Loss Trial With Inato

-
Inato
5
min
April 17, 2026
181 Hours and $4,500 Saved: Inside One Weight Loss Trial With Inato
Sponsors

Asthma Case Study: 181% of Inato’s patient enrollment achieved

Events

SCOPE Orlando 2026 Recap: How Data-Driven Sites Can Prove Patient Access to Win Trials and Accelerate Enrollment

-
Inato
5
min
February 13, 2026
SCOPE Orlando 2026 Recap: How Data-Driven Sites Can Prove Patient Access to Win Trials and Accelerate Enrollment

Join the global platform driving faster, more accessible trials.